| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/24/2015 | US8962596 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases |
| 02/24/2015 | US8962559 Sustained release formulations comprising GNRH analogues |
| 02/24/2015 | CA2771403C Quinoline derivative-containing pharmaceutical composition |
| 02/24/2015 | CA2658633C Chiral compounds substituted with phosphonic acid ester functions or phosphonic acid functions |
| 02/24/2015 | CA2656419C Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| 02/24/2015 | CA2640528C Oncolytic adenoviruses for cancer treatment |
| 02/24/2015 | CA2630717C Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| 02/24/2015 | CA2602324C Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer |
| 02/24/2015 | CA2573430C Anti-perp antibody |
| 02/24/2015 | CA2531238C Polypeptides having binding affinity for her2 |
| 02/24/2015 | CA2489467C Humanized monoclonal antibody hpam4 |
| 02/24/2015 | CA2479288C Process for producing cytotoxic lymphocyte |
| 02/19/2015 | WO2015023915A1 Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| 02/19/2015 | WO2015023879A1 Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
| 02/19/2015 | WO2015023851A1 Antibodies against frizzled proteins and methods of use thereof |
| 02/19/2015 | WO2015023703A1 Methods for the treatment of her2 amplified cancer |
| 02/19/2015 | WO2015023552A1 Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types |
| 02/19/2015 | WO2015023551A1 Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types |
| 02/19/2015 | WO2015023355A1 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| 02/19/2015 | WO2015023064A1 Method for preparing highly-pure pemetrexed disodium salt |
| 02/19/2015 | WO2015022926A1 Novel fused pyrimidine compound or salt thereof |
| 02/19/2015 | WO2015022664A1 Compounds and compositions as inhibitors of mek |
| 02/19/2015 | WO2015022663A1 Compounds and compositions as inhibitors of mek |
| 02/19/2015 | WO2015022662A1 Compounds and compositions as inhibitors of mek |
| 02/19/2015 | WO2015022657A1 Pharmaceutical combinations |
| 02/19/2015 | WO2015022609A1 Combination therapy for the treatment of cancer |
| 02/19/2015 | WO2015022546A1 Inhibitors of plasma kallikrein |
| 02/19/2015 | WO2015022407A1 Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid |
| 02/19/2015 | WO2015022332A1 Pyridinones |
| 02/19/2015 | WO2015022200A1 Metallo-acylhydrazone complexes and use thereof in preventing the development of or eliminating tumoral resistance to cytostatics and for treating tumours (anti-tumour agents) |
| 02/19/2015 | WO2015022038A1 3-substituted cyclopentylamine derivatives |
| 02/19/2015 | WO2015021936A1 Method and compositions for treating cancer using probiotics cross-reference to related application |
| 02/19/2015 | WO2015021929A1 Combined application of isothiocyanate compound and anti-cancer medicine |
| 02/19/2015 | WO2015021922A1 Ginsenoside rd or enteric formulation thereof and use |
| 02/19/2015 | WO2015021894A1 Novel hydroximic acid derivative and medical application thereof |
| 02/19/2015 | WO2015021833A1 Conjugated diene derivatives, preparation method therefor, and uses thereof as anticancer drug |
| 02/19/2015 | WO2015021817A1 Use of recombinant ganoderma lucidum immunomodulatory protein (rlz-8) in preparation of medicine for treating melanoma |
| 02/19/2015 | WO2015021741A1 Use of doxycycline |
| 02/19/2015 | WO2015021704A1 Uses of doxycycline for preparing antitumor drugs |
| 02/18/2015 | EP2837685A1 Anti-fgfr2 antibody |
| 02/18/2015 | EP2837631A1 New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
| 02/18/2015 | EP2837387A1 Anticancer agent |
| 02/18/2015 | EP2837383A1 Immunity-inducing agent |
| 02/18/2015 | EP2837381A1 Use of agents that alter the peritumoral environment for the treatment of cancer |
| 02/18/2015 | EP2836494A1 New alkylating agents |
| 02/18/2015 | EP2836493A1 Functionalized thieno-indole derivatives for the treatment of cancer |
| 02/18/2015 | EP2836491A1 Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| 02/18/2015 | EP2836490A2 Indole and indazole compounds that activate ampk |
| 02/18/2015 | EP2836487A1 Heterocyclic compounds and uses thereof |
| 02/18/2015 | EP2836482A1 Compositions and methods for treating cancer |
| 02/18/2015 | EP2836481A1 Methods and compositions for treating ewings sarcoma family of tumors |
| 02/18/2015 | EP2836478A2 Coriolus versicolor extracts, methods of isolating biologically-active compounds, and uses thereof |
| 02/18/2015 | EP2836238A1 Co-polymer conjugates |
| 02/18/2015 | EP2836220A1 Methods for bladder cancer therapy using baculoviral vectors |
| 02/18/2015 | EP2836217A1 Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents |
| 02/18/2015 | EP2836216A1 Combination therapy for treating cancer |
| 02/18/2015 | EP2836199A1 Fulvestrant formulations |
| 02/18/2015 | EP2591799A9 Cancer peptide vaccine |
| 02/17/2015 | US8957184 Pro-apoptotic peptides |
| 02/17/2015 | US8957065 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| 02/17/2015 | US8957027 Deacetylase inhibitor therapy |
| 02/17/2015 | US8957015 Tumor suppressor gene p47ING3 |
| 02/17/2015 | US8956648 Calciumphosphate-based nanoparticles as carrier-systems for photodynamic therapy |
| 02/17/2015 | US8956621 Compositions and methods for treatment of cervical dysplasia |
| 02/17/2015 | CA2726579C Novel uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity |
| 02/17/2015 | CA2710977C 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin d analogs |
| 02/17/2015 | CA2664744C Triphenylphosphonium thionitrite nitric oxide donors |
| 02/17/2015 | CA2651136C Substituted thieno-fused pyrimidines as p13k inhibitors |
| 02/17/2015 | CA2647423C Triazolone derivative |
| 02/17/2015 | CA2635842C Prokineticin 1 receptor antagonists |
| 02/17/2015 | CA2635623C Anti-cd19 antibodies with reduced immunogenicity |
| 02/17/2015 | CA2611389C Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
| 02/17/2015 | CA2592509C Benzazole analogues and uses thereof |
| 02/17/2015 | CA2563103C Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer |
| 02/17/2015 | CA2511814C Polymer conjugates of interferon-beta with enhanced biological potency |
| 02/12/2015 | WO2015021456A1 Small molecules to enhance p53 activity |
| 02/12/2015 | WO2015021376A1 Immunoglobulin expression levels as biomarker for proteasome inhibitor response |
| 02/12/2015 | WO2015021324A1 Filanesib combined with pomalidomide displays enhanced anti-tumor activity |
| 02/12/2015 | WO2015021305A1 Cancer cell specific imaging probes and methods of use |
| 02/12/2015 | WO2015021155A1 Methods of treatment of hpv related diseases |
| 02/12/2015 | WO2015021128A1 Kdm1a inhibitors for the treatment of disease |
| 02/12/2015 | WO2015020960A1 Novel lncrna polynucleotides |
| 02/12/2015 | WO2015020929A2 Rasal1 is a major tumor suppressor gene in thyroid cancer |
| 02/12/2015 | WO2015020565A1 Substituted [1,2,4]triazolo[4,3-a]pyridines exhibiting antagonist properties to adenosine a2a receptors, and use thereof |
| 02/12/2015 | WO2015020553A1 Carbazole compounds and methods of using same |
| 02/12/2015 | WO2015020215A1 Lentiviral vector thtd, aging agent, cancer inhibitor, and medicinal composition containing said thtd, protein packaged in viruslike hollow particle, and production method for viruslike hollow particle |
| 02/12/2015 | WO2015020212A1 Pharmaceutical composition for treatment and/or prevention of cancer |
| 02/12/2015 | WO2015020122A1 Urothelial cancer diagnosis and therapeutic agent |
| 02/12/2015 | WO2015020040A1 Medicine for preventing or suppressing survival of cancer cells and having organic acid polymer as active ingredient |
| 02/12/2015 | WO2015019505A1 Lentiviral vector thtd and senescence-promoting material containing thtd |
| 02/12/2015 | WO2015019320A1 Pim kinase inhibitor combinations |
| 02/12/2015 | WO2015019318A1 Peptides capable of reactivating p53 mutants |
| 02/12/2015 | WO2015019296A1 Ruthenium complexes with antitumoral chemotherapy activities |
| 02/12/2015 | WO2015019284A2 Inhibition of cxcr4 signaling in cancer immunotherapy |
| 02/12/2015 | WO2015019269A1 Labelled ligands of anti-mullerian hormone for the diagnosis of endometriosis |
| 02/12/2015 | WO2015019230A1 Bag3 receptor binding molecules for use as a medicament |
| 02/12/2015 | WO2015019121A1 Styryl quinazoline derivatives as pharmaceutically active agents |
| 02/12/2015 | WO2015019037A1 Pharmaceutical compounds |
| 02/12/2015 | WO2015019030A1 Novel combination of 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-n-methylnaphthalene-1-carboxamide and an anti-oestrogen in breast cancer |
| 02/12/2015 | WO2015018529A1 Combined pharmaceutical composition |